Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside ...

The webcast of the fireside chat will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.

Simultaneous expansion and activation of both major γδ T cell subsets (Vδ1+ and Vδ2+) leverages both the rapid antigen presenting properties of Vδ2+ T cells and the longer-term resistance against ...

To request a meeting, please contact your ROTH sales representative. About Synergy CHC Corp.

PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) -- Instinct Science, a leader in veterinary software innovation, announces the launch of Standards of Care™ (standards.vet), a next-generation clinical ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a ...

Operating Income was € (120.4) million compared to € (234.3) million in 2023. Financial income was € (19.2) million, compared with € (8.5) million in 2023, due to the increase in interest rates and ...

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, ...

Today’s actions expand on Arbutus and Genevant’s ongoing enforcement proceeding in the U.S. District Court for the District of Delaware, seeking fair compensation for Moderna’s alleged infringement of ...

ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center ( Health-ISAC ), the non-profit industry-led organization that provides the global health sector with a ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...

The Phase 3 ARTEMIS trial (NCT06856577) is designed to evaluate the safety and efficacy of Ixo-vec in a randomized (1:1), double-masked, sham-controlled, two-arm study. The US-based trial is intended ...